SEARCH

SEARCH BY CITATION

11.0 References

  • 1
    Health Protection Agency. HIV in the United Kingdom: 2010 report. Health Protection Report 2010; 4(Number 47): 89. Available at http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287145367237 (accessed April 2012).
  • 2
    Data tables of the unlinked anonymous dried blood spot survey of newborn infants- prevalence of HIV in women giving birth. Surveillance update. Health Protection Agency 2010; Available at http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1287144874352 (accessed April 2012).
  • 3
    Duong T, Ades AE, Gibb D, Tookey P, Masters J. Vertical transmission rates for HIV on the British Isles: estimates based on surveillance data. BMJ 1999; 319: 12271229.
  • 4
    Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973981.
  • 5
    National Study of HIV in Pregnancy and Childhood. National surveillance data. 2012. Available at http://www.nshpc.ucl.ac.uk (accessed April 2012).
  • 6
    Health Protection Agency. United Kingdom: new HIV diagnoses data to end June 2011. Health Protection Agency 2011. Available at http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1237970242135 (accessed April 2012).
  • 7
    Judd A, Doerholt K, Tookey PA et al. Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996–2006: planning for teenage and adult care. Clin Infect Dis 2007; 45: 918924.
  • 8
    Collaborative HIV Paediatric Study. 2011. Available at http://www.chipscohort.ac.uk/default.asp (accessed April 2012).
  • 9
    Kenny J, Williams B, Prime K, Tookey P, Foster C. Pregnancy outcomes in adolescents in the UK and Ireland growing up with HIV. HIV Med 2012; 13: 304308.
  • 10
    Intercollegiate Working Party. Reducing Mother to Child Transmission of HIV Infection in the United Kingdom. 2006. Available at http://www.rcpch.ac.uk/sites/default/files/asset_library/Publications/R/HIVreport.pdf (accessed April 2012).
  • 11
    Townsend CL, Cliffe S, Tookey PA. Uptake of antenatal HIV testing in the United Kingdom: 2000–2003. J Public Health 2006; 28: 248252.
  • 12
    UK National Screening Committee. Infectious diseases in pregnancy screening programme: programme standards. NHS Screening programmes. 2010. Available at http://infectiousdiseases.screening.nhs.uk/standards (accessed April 2012).
  • 13
    UK National Screening Committee. Infectious diseases in pregnancy screening programme: 2008–2009 annual report. NHS Screening Programmes. 2010. Available at http://infectiousdiseases.screening.nhs.uk/publications (accessed April 2012).
  • 14
    AIAU, NSHPC, CHIVA. Perinatal Transmission of HIV in England 2002–2005. Audit, Information and Analysis Unit. 2007. Available at http://www.nshpc.ucl.ac.uk/Audit/Vertical_Transmission_Executive_SummaryOctober_2007.pdf (accessed April 2012).
  • 15
    Madge S, Phillips AN, Griffioen A, Olaitan A, Johnson MA. Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV. Int J Epidemiol 1998; 27: 10681071.
  • 16
    Leroy V, De Clerq A, Ladner J, Bogaerts J, Van der Perre P, Dabis F. Should screening of genital infections be part of antenatal care in areas of high HIV prevalence? A prospective cohort study from Kigali, Rwanda, 1992–1993. The pregnancy and HIV (EGE) Group. Genitourin Med 1995; 71: 207211.
  • 17
    Low N, Sterne JAC, Barlow D. Inequalities in rates of gonorrhoea and chlamydia between black ethnic groups in south east London: cross sectional study. Sex Transm Infect 2001; 77: 1520.
  • 18
    Chuachoowong R, Shaffer N, Siriwasin W et al. Short- course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 2000; 181: 99106.
  • 19
    Hart CE, Lennox JL, Pratt-Palmore M et al. Correlation of human immunodeficiency virus type 1 RNA levels in blood and female genital tract. J Infect Dis 2000; 179: 871882.
  • 20
    Fiore JR, Suligoi B, Saracino A et al. Correlates of HIV-1 shedding in cervicovaginal secretions and effects of antiretroviral therapies. AIDS 2003; 17: 169176.
  • 21
    Kovacs A, Wasserman SS, Burns D et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358: 15931601.
  • 22
    de Pasquale MP, Leigh-Brown AJ, Cu-Uvin S et al. Differences in HIV-1 pol sequences from female genital tract and blood during antiretroviral therapy. J Acquir Immune Defic Syndr 2003; 34: 3744.
  • 23
    Warszawaski J, Tubiana R, Le Chenadec J et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008; 22: 289299.
  • 24
    Cameron DW, Simonsen JN, D'Costa LJ et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989; ii: 403407.
  • 25
    Dickerson MC, Johnston J, Delea TE, White A, Andrews E. The causal role for genital ulcer disease as a risk factor for transmission of human immunodeficiency virus. An application of the Bradford Hill criteria. Sex Transm Dis 1996; 23: 429440.
  • 26
    Ghys PD, Fransen K, Diallo MO et al. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d'Ivoire. AIDS 1997; 11: F85F93.
  • 27
    Lawn SD, Subbarao S, Wright JTC et al. Correlation between human immunodeficiency virus type 1 RNA levels in the female genital tract and immune activation associated with ulceration of the cervix. J Infect Dis 2000; 181: 19501956.
  • 28
    Hashemi FB, Ghassemi M, Roebuck KA, Spear GT. Activation of human immunodeficiency virus type 1 expression by Gardnerella vaginalis . J Infect Dis 1999; 179: 924930.
  • 29
    Hashemi FB, Ghassemi M, Faro S, Aroutcheva A, Spear GT. Induction of human immunodeficiency virus type 1 expression by anaerobes associated with bacterial vaginosis. J Infect Dis 2000; 181: 15741580.
  • 30
    McClelland RS, Wang CC, Mandaliya K et al. Treatment of cervicitis is associated with decreased cervical shedding of HIV-1. AIDS 2001; 15: 105110.
  • 31
    Cowan FM, Humphrey JH, Ntozini R, Mutasa K, Morrow R, Iliff P. Maternal herpes simplex virus type 2 infection, syphilis and risk of intra-partum transmission of HIV-1: results of a case control study. AIDS 2008; 22: 193201.
  • 32
    Bollen LJ, Whitehead SJ, Mock PA et al. Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission? AIDS 2008; 22: 11691176.
  • 33
    Ouedraogo A, Nagot N, Vergne L et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS 2006; 20: 23052313.
  • 34
    Patterson J, Hitti J, Selke S et al. Genital HSV detection among HIV-1-infected pregnant women in labor. Infect Dis Obstet Gynecol 2011; 2011: 157680.
  • 35
    Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 15001507.
  • 36
    Hillier SL, Martius J, Krohn M, Kiviat N, Holmes KK, Eschenbach DA. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319: 972978.
  • 37
    Landesman SH, Kalish LA, Burns DN et al. Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The Women and Infants Transmission Study. N Engl J Med 1996; 334: 16171623.
  • 38
    Newell ML, Dunn DT, Peckham CS, Semprini AE, Pardi G. Vertical transmission of HIV-1: maternal immune status and obstetric factors: the European Collaborative Study. AIDS 1996; 10: 16751681.
  • 39
    Van Dyke RB, Korber BT, Popek E et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999; 179: 319328.
  • 40
    Taha TE, Brown ER, Hoffman IF et al. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006; 20: 13131321.
  • 41
    Hillier SL, Nugent RP, Eschenbach DA et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. N Engl J Med 1995; 333: 17371742.
  • 42
    Taha TE, Gray RH. Genital tract infections and perinatal transmission of HIV. Ann N Y Acad Sci 2000; 918: 8498.
  • 43
    McDonald H, Brocklehurst P, Parsons J, Vigneswaran R. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2003; (2)CD000262.
  • 44
    Varma R, Gupta JK, James DK, Kilby MD. Do screening- preventative interventions in asymptomatic pregnancies reduce the risk of preterm delivery. A critical appraisal of the literature. Eur J Obstet Gynecol Reprod Biol 2006; 127: 145159.
  • 45
    Farquhar C, Mbori-Ngacha D, Overbaugh J et al. Illness during pregnancy and bacterial vaginosis are associated with in-utero HIV-1 transmission. [Letter]. AIDS 2010; 24: 153155.
  • 46
    McDonald HM, Brocklehurst P, Gordon A. Antibiotics for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev 2007; (1)CD000262.
  • 47
    Fakoya A, Lamba H, Mackie N et al. 2007 UK guidelines for the management of sexual and reproductive health (SRH) of people living with HIV infection. HIV Med 2008; 9: 681720.
  • 48
    Luesley D, Leeson S. Colposcopy and programme management. In: Sheffield, NHS Cancer Screening Programmes, 2010: 159. Guidelines for the NHS Cervical Screening Programme, 2nd edn. NHSCSP Publication No. 20 May 2010. Available at http://www.cancerscreening.nhs.uk/cervical/publications/nhscsp20.pdf (accessed April 2012).
  • 49
    Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011. Wilmington, NC, Registry Coordinating Center, 2011: Available at http://www.APRegistry.com (accessed April 2012).
  • 50
    de Ruiter A, Mercey D, Anderson J et al. British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Med 2008; 9: 452502.
  • 51
    Nightingale SL. From the food and drug administration. JAMA 1998; 280: 1472.
  • 52
    Fundaro C, Genovese O, Rendeli C, Tamburrini E, Salvaggio E. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 2002; 16: 299300.
  • 53
    Saitoh A, Hull AD, Franklin P, Spector SA. Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 2005; 25: 555556.
  • 54
    Ekouevi DK, Coffie PA, Ouattara E et al. Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 56: 183187.
  • 55
    Ford N, Mofenson L, Kranzer K et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010; 24: 14611470.
  • 56
    Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 2011; 25: 23012304.
  • 57
    Brogly SB, Abzug MJ, Watts DH et al. Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 2010; 29: 721727.
  • 58
    Knapp KM, Brogly SB, Muenz DG et al. Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 2012; 31: 164170.
  • 59
    Joao EC, Calvet GA, Krauss MR et al. Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 2010; 53: 176185.
  • 60
    Townsend CL, Willey BA, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS 2009; 23: 519524.
  • 61
    Connor EM, Sperling RS, Gelber R et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 11731180.
  • 62
    Tariq S, Townsend CL, Cortina-Borja M et al. Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009. J Acquir Immune Defic Syndr 2011; 57: 326333.
  • 63
    Tubiana R, Matheron S, Le Chenadec J et al. Extremely low risk of MTCT of HIV in women starting HAART before pregnancy: French Perinatal Cohort, ANRS EPF CO1/11. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 2011 [Abstract 735].
  • 64
    Lallemant M, Jourdain G, Ngo-Giang-Huong N et al. A phase III randomized, partially double-blind and placebo-controlled trial comparing the efficacy and safety of maternal and infant NVP vs infant only NVP, or maternal LPV/r, in addition to standard ZDV prophylaxis to prevent perinatal HIV transmission: Thailand, PHPT-5. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2011 [Abstract 741].
  • 65
    US Food and Drug Administration. Important drug warning. Videx (didanosine) and Zerit (stavudine) Dear Healthcare Professional Letter Jan 2001. [Retyped letter from Bristol-Myers Squibb Company, dated 5 January 2001]. 2001 Available at http://www.fda.gov/Safety/%20MedWatch/SafetyInformation/SafetyAlertsforHumanMedical%20Products/ucm172676.htm (accessed April 2012).
  • 66
    Shapiro RL, Hughes MD, Ogwu A et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med 2010; 362: 22822294.
  • 67
    European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40: 458465.
  • 68
    Edwards S, Larbalestier N, Hay P et al. Experience of nevirapine use in a London cohort of HIV infected pregnant women. HIV Med 2001; 2: 8991.
  • 69
    Natarajan U, Pym A, McDonald C et al. The safety of nevirapine in pregnancy. HIV Med 2007; 8: 6469.
  • 70
    Ouyang DW, Brogly SB, Lu M et al. Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals. AIDS 2010; 24: 109114.
  • 71
    Phanuphak N, Apornpong T, Intarasuk S, Teeratakulpisarn S, Phanuphak P. Toxicities from nevirapine in HIV-infected males and females, including pregnant females with various CD4 cell counts. 12th Conference on Retroviruses and Opportunistic Infections. Boston MA. February 2005 [Abstract 22].
  • 72
    Mirochnick M, Siminski S, Fenton T, Lugo M, Sullivan JL. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. Pediatr Infect Dis J 2001; 20: 803805.
  • 73
    Mirochnick M, Fenton T, Gagnier P et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type-1 infected pregnant women and their neonates. J Infect Dis 1998; 178: 368374.
  • 74
    Taylor GP, Lyall E, Back D, Ward C, Tudor-Williams G. Pharmacological implications of prolonged in utero exposure to nevirapine. Lancet 2000; 355: 21342135.
  • 75
    Brooks Jackson J, Musoke P, Fleming T et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18 month follow-up of the HIVNET 012 randomised trial. Lancet 2003; 362: 859868.
  • 76
    Dabis F, Bequent L, Ekouevi DK et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19: 309318.
  • 77
    Lallemant M, Jourdain G, Le Couer S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 2004; 351: 217228.
  • 78
    de Vincenzi I, Kesho Bora Study Group. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171180.
  • 79
    Samuel M, Bradshaw D, Perry M et al. Atazanavir in pregnancy: a report of 155 cases. HIV Med 2011; 12 (Suppl 1): 9. [Abstract O25].
  • 80
    van der Lugt J, Colbers A, Molto J et al. The pharmacokinetics, safety and efficacy of boosted saquinavir tablets in HIV type-1-infected pregnant women. Antivir Ther 2009; 14: 443450.
  • 81
    Vithayasai V, Moyle GJ, Supajatura V et al. Safety and efficacy of saquinavir soft-gelatin capsules plus zidovudine plus optional lamivudine in pregnancy and prevention of vertical HIV transmission. J Acquir Immune Defic Syndr 2002; 30: 410412.
  • 82
    Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007; 44: 16471656.
  • 83
    Read PJ, Mandalia S, Khan P et al. When should HAART be initiated in pregnancy to achieve an undetectable HIV viral load by delivery? AIDS 2012; 26(9): 10951103.
  • 84
    Kay N, Fish R, Duncan S et al. The impact of HAART on HIV RNA decay during the first 2 weeks of therapy among HIV+ pregnant women. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. March 2012 [Abstract 1020].
  • 85
    Lorenzi P, Spicher VM, Laubereau B et al. Antiretroviral therapies in pregnancy: maternal, foetal and neonatal effects. AIDS 1998; 12: F241F247.
  • 86
    European Collaborative Study, Swiss Mother and Child HIV Cohort Study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000; 14: 29132930.
  • 87
    European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 380387.
  • 88
    European Collaborative Study. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 2004; 18: 23372339.
  • 89
    Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 2007; 21: 10191026.
  • 90
    Tuomala RE, Shapiro DE, Mofenson LM et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002; 346: 18631870.
  • 91
    Tuomala RE, Watts DH, Li D et al. Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy. J Acquir Immune Defic Syndr 2005; 38: 449473.
  • 92
    Schulte J, Dominguez K, Sukalac T, Bohannon B, Fowler M. G, for the Pediatric Spectrum of HIV Disease Consortium. Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: pediatric Spectrum of HIV Disease, 1989–2004. Pediatrics 2007; 119: e900e906.
  • 93
    Cotter AM, Garcia AG, Duthely ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth? J Infect Dis 2006; 193: 11951201.
  • 94
    Kourtis AP, Schmid CH, Jamieson DJ, Lau J. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 2007; 21: 607615.
  • 95
    Beckerman K, Albano J, Cohan D, Watts DH, Tilson H. Exposure to combination antiretroviral (cARV) regimens containing protease inhibitors (PI) during pregnancy and prevalence of low birth weight/preterm delivery (LBW/PTD) among women with low pre-existing risk for LBW/PTD: a stratified analysis of 10,082 pregnancies. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome. July 2011 [Abstract TULBPE018].
  • 96
    Machado ES, Hofer CB, Costa TT et al. Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conception. Sex Transm Infect 2009; 85: 8287.
  • 97
    Martin F, Taylor GP. Increased rates of pre-term delivery are associated with the initiation of highly active antiretroviral therapy during pregnancy: a single centre cohort study. J Infect Dis 2007; 196: 558561.
  • 98
    Patel K, Shapiro DE, Brogly S et al. Prenatal protease inhibitor use and risk of preterm birth among HIV-1 infected women initiating antiretroviral drugs during pregnancy. J Infect Dis 2010; 201: 10351044.
  • 99
    Sibiude J, Warszawski J, Tubiana R et al. Large increase in prematurity between 1990 and 2009 in HIV-infected women in the National ANRS French Perinatal Cohort: does ritonavir boost play a role? 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2011 [Abstract 743].
  • 100
    Hamilton BE, Martin JA, Ventura SJ. Births: preliminary data for 2010. Natl Vital Stat Rep 2011; 60: 45 Available at http://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_02.pdf (accessed April 2012).
  • 101
    Powis KM, Kitch D, Ogwu A et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis 2011; 204: 506514.
  • 102
    Kesho Bora Study Group, de Vincenzi I. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial. Lancet Infect Dis 2011; 11: 171180.
  • 103
    Roberts SS, Martinez M, Covington DL, Rode RA, Pasley MV, Woodward WC. Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr 2009; 51: 456461.
  • 104
    Rodman JH, Flynn PM, Robbins B et al. Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type-1 infected women and newborn infants. J Infect Dis 1999; 180: 18441850.
  • 105
    Odinecs A, Nosbich C, Keller RD, Baughman WL, Unadkat J. In vivo maternal-fetal pharmacokinetics of stavudine (2′,3′-didehydro-3′-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40: 196202.
  • 106
    Moodley J, Moodley D, Pillay K et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178: 13271333.
  • 107
    Best BM, Mirochnick M, Capparelli E et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20: 553560.
  • 108
    Wang Y, Livingston E, Patil S et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected women and their neonates: an AIDS Clinical Trials Group study. J Infect Dis 1999; 180: 15361541.
  • 109
    Burchett S, Best B, Mirochnick M et al. Tenofovir pharmacokinetics during pregnancy, at delivery and post partum. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, Ca. February 2007 [Abstract 738b].
  • 110
    Benaboud S, Hirt D, Launay O et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012; 56: 857862.
  • 111
    Hirt D, Urien S, Ekouevi DK et al. Population pharmacokinetics of tenofovir in HIV-1-infected pregnant women and their neonates (ANRS 12109). Clin Pharmacol Ther 2009; 85: 182189.
  • 112
    Stek A, Best B, Luo W et al. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med 2012; 13: 226235.
  • 113
    Cressey TR, Stek A, Capparelli E et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2011 [Abstract 754].
  • 114
    Aweeka F, Stek A, Best BM et al. Lopinavir protein binding in HIV-1 infected pregnant women. HIV Med 2010; 11: 232238.
  • 115
    Best BM, Stek AM, Mirochnick M et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2010; 54: 381388.
  • 116
    Else LJ, Douglas M, Dickinson L, Back DJ, Khoo SH, Taylor GP. Improved oral bioavailability of lopinavir in melt-extruded tablet formulation reduces impact of third trimester on lopinavir plasma concentrations. Antimicrob Agents Chemother 2012; 56: 816824.
  • 117
    Lyons F, Lechelt M, de Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS 2007; 21: 10531054.
  • 118
    Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430436.
  • 119
    Ripamonti D, Cattaneo D, Maggiolo F et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21: 24092415.
  • 120
    Mirochnick M, Best BM, Stek AM et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. J Acquir Immune Defic Syndr 2011; 56: 412419.
  • 121
    Colbers A, Molto J, Ivanovic J et al. A comparison of the pharmacokinetics of darunavir, atazanavir and ritonavir during pregnancy and post-partum. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, WA. March 2012 [Abstract 1013].
  • 122
    Conradie F, Zorrilla C, Josipovic D et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med 2011; 12: 570579.
  • 123
    Capparelli E, Best BM, Stek A et al. Pharmacokinetics of darunavir once or twice daily during and after pregnancy. In: 3rd International Workshop on HIV Pediatrics. Rome, 2011. [Abstract P_72].
  • 124
    Cespedes M, Ford S, Pakes G, Vargas L, De Candia E, Aberg J. Pharmacokinetics, cord blood concentrations, and tolerability of boosted fosamprenavir in pregnancy. 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy. July 2011 [Abstract TUPE278].
  • 125
    Best BM, Capparelli EV, Stek A et al. Raltegravir pharmacokinetics during pregnancy. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA. September 2010 [Abstract H-1668a].
  • 126
    Colbers A, Molto J, Ivanovir J et al. A comparison of the pharmacokinetics of raltegravir during pregnancy and post-partum. 12th International Workshop on Clinical Pharmacology of HIV Therapy. Miami, FL. April 2011 [Abstract P_18].
  • 127
    Ceccaldi PF, Ferreira C, Gavard L, Gil S, Peytavin G, Mandelbrot L. Placental transfer of enfuvirtide in the ex vivo human placenta perfusion model. Am J Obstet Gynecol 2008; 198: 433.e1–2.
  • 128
    Peytavin G, Tubiana R, Ferreira C et al. Genital tract diffusion of different HIV PI in HIV-1 infected pregnant women. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA. February 2007 [Abstract 744].
  • 129
    Dumond J, Yeh R, Patterson K et al. First dose and steady-state genital tract pharmacokinetics of ten antiretroviral drugs in HIV-infected women: implications for pre- and post- exposure prophylaxis. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO. February 2006 [Abstract 129].
  • 130
    Shaffer N, Chuachoowong R, Mock PA et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet 1999; 353: 773780.
  • 131
    The European Mode of Delivery Collaboration. Elective caesarian-section versus vaginal delivery in prevention of vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999; 353: 10351039.
  • 132
    Lyall E, Blott M, de Ruiter A et al. Guidelines for the Management of HIV infection in pregnant women and the prevention of mother-to-child transmission. British HIV Association. HIV Med 2001; 2: 314334.
  • 133
    Read P, Khan P, Mandalia S et al. When should HAART be initiated in pregnancy to achieve an undetectable viral load? 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA. February 2010 [Abstract 896].
  • 134
    Markowitz M, Morales-Ramirez JO, Nguyen BY et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naïve HIV-1-infected individuals. J Acquir Immune Defic Syndr 2006; 43: 509515.
  • 135
    Murray JM, Emery S, Kelleher AD et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 2007; 21: 23152321.
  • 136
    Musoke P, Guay LA, Bagenda D et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1 infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS 1999; 13: 479486.
  • 137
    McKeown DA, Rosenvinge M, Donaghy S et al. High neonatal concentrations of raltegravir following transplacental transfer in HIV-1 positive pregnant women. AIDS 2010; 24: 24162418.
  • 138
    Wade NA, Birkhead GS, Warren BL et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998; 339: 14091414.
  • 139
    Hirt D, Ekouevi DK, Pruvost A et al. Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother 2011; 55: 29612967.
  • 140
    Walker BD. Elite control of HIV infection: implications for vaccines and treatment. Top HIV Med 2007; 15: 134136.
  • 141
    Ioannidis JP, Abrams EJ, Ammann AJ et al. Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml. J Infect Dis 2001; 183: 539545.
  • 142
    Rutland E, Mani R. Management of pregnancy in an HIV elite controller. Int J STD AIDS 2010; 21: 604605.
  • 143
    Sperling RS, Shapiro DE, Coombs RW et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335: 16211629.
  • 144
    Watts DH, Lambert J, Stiehm ER et al. Progression of HIV disease among women following delivery. J Acquir Immune Defic Syndr 2003; 33: 585593.
  • 145
    Melekhin VV, Shepherd BE, Jenkins CA et al. Postpartum discontinuation of antiretroviral therapy and risk of maternal AIDS-defining events, non-AIDS-defining events, and mortality among a cohort of HIV-1-infected women in the United States. AIDS Patient Care STDS 2010; 24: 279286.
  • 146
    Melo VH, Pinto JA, Freimanis-Hance L et al. Postpartum changes in plasma viral load and CD4 percentage among HIV-infected women from Latin American and Caribbean countries: the NISDI Perinatal Study. Mem Inst Oswaldo Cruz 2011; 106: 97104.
  • 147
    Onen NF, Nurutdinova D, Sungkanuparph S, Gase D, Mondy K, Overton ET. Effect of postpartum HIV treatment discontinuation on long-term maternal outcome. J Int Assoc Physicians AIDS Care (Chic) 2008; 7: 245251.
  • 148
    Watts DH, Lu M, Thompson B et al. Treatment interruption after pregnancy: effects on disease progression and laboratory findings. Infect Dis Obstet Gynecol 2009; 2009: 456717.
  • 149
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 150
    Danel C, Moh R, Minga A et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367: 19811989.
  • 151
    Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 18151826.
  • 152
    Sterne JA, May M, Costagliola D et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 13521363.
  • 153
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2012; 1239. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed April 2012).
  • 154
    Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321333.
  • 155
    Bardeguez AD, Shapiro DE, Mofenson LM et al. Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival. J Acquir Immune Defic Syndr 2003; 32: 170181.
  • 156
    Martin F, Navaratne L, Khan W et al. Pregnant women with HIV infection can expect healthy survival. J Acquir Immune Defic Syndr 2006; 43: 186192.
  • 157
    Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493505.
  • 158
    Pogany K, van Valkengoed IG, Prins JM et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr 2007; 44: 395400.
  • 159
    Ananworanich J, Gayet-Ageron A, Le BM et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368: 459465.
  • 160
    Steingrover R, Pogany K, Fernandez GE et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS 2008; 22: 15831588.
  • 161
    Palacios R, Senise J, Vaz M, Diaz R, Castelo A. Short-term antiretroviral therapy to prevent mother-to-child transmission is safe and results in a sustained increase in CD4 T-cell counts in HIV-1-infected mothers. HIV Med 2009; 10: 157162.
  • 162
    Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571577.
  • 163
    Rouet F, Chaix ML, Inwoley A et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74: 3440.
  • 164
    Konopnicki D, Mocroft A, De WS et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593601.
  • 165
    Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14: e1024e1031.
  • 166
    Euler GL, Wooten KG, Baughman AL, Williams WW. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting, and preventing perinatal transmission. Pediatrics 2003; 111 (5 Part 2): 11921197.
  • 167
    Lacombe K, Bottero J, Lemoine M, Boyd A, Girard PM. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2010; 65: 1017.
  • 168
    Tiribelli C, Rigato I. Liver cirrhosis and pregnancy. Ann Hepatol 2006; 5: 201.
  • 169
    Brook G, Main J, Nelson M et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11: 130.
  • 170
    Panel for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. 2010. Department of Health and Human Services Available at http://www.aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0/ (accessed April 2012).
  • 171
    American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: viral hepatitis in pregnancy. Obstet Gynecol 2007; 110: 941956.
  • 172
    Avihingsanon A, Lewin SR, Kerr S et al. Efficacy of tenofovir disoproxil fumarate/emtricitabine compared with emtricitabine alone in antiretroviral-naïve HIV-HBV coinfection in Thailand. Antivir Ther 2010; 15: 917922.
  • 173
    Matthews GV, Avihingsanon A, Lewin SR et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology 2008; 48: 10621069.
  • 174
    Xu WM, Cui YT, Wang L et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009; 16: 94103.
  • 175
    Bellini C, Keiser O, Chave JP et al. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. HIV Med 2009; 10: 1218.
  • 176
    Yang J, Zeng XM, Men YL, Zhao LS. Elective caesarean section versus vaginal delivery for preventing mother to child transmission of hepatitis B virus – a systematic review. Virol J 2008; 5: 100.
  • 177
    Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010; 116: 147159.
  • 178
    Han G, Jiang H, Zhao W, Ge C, Xu C, Pan C. Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission (vt) of chronic hepatitis B (CHB) in highly viremic mothers. The Liver Meeting. San Francisco, CA. November 2011 [Abstract]. Available at http://www.aasld.org/lm2011/abstracts/Pages/default.aspx (accessed April 2012).
  • 179
    Landes M, Newell ML, Barlow P et al. Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe. HIV Med 2008; 9: 526534.
  • 180
    Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol 1998; 27: 108117.
  • 181
    Polis CB, Shah SN, Johnson KE, Gupta A. Impact of maternal HIV coinfection on the vertical transmission of hepatitis C virus: a meta-analysis. Clin Infect Dis 2007; 44: 11231131.
  • 182
    Pappalardo BL. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 2003; 32: 727734.
  • 183
    European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. Br J Obstet Gynaecol 2001; 108: 371377.
  • 184
    Hershow RC, Riester KA, Lew J et al. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study. J Infect Dis 1997; 176: 414420.
  • 185
    Zanetti AR, Tanzi E, Romano L et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208212.
  • 186
    Ngo-Giang-Huong N, Jourdain G, Sirirungsi W et al. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int J Infect Dis 2010; 14: e602e607.
  • 187
    Mast EE, Hwang LY, Seto DS et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192: 18801889.
  • 188
    European Paediatric Hepatitis C Virus Network. A significant sex–but not elective cesarean section–effect on mother-to-child transmission of hepatitis C virus infection. J Infect Dis 2005; 192: 18721879.
  • 189
    England K, Thorne C, Newell ML. Vertically acquired paediatric coinfection with HIV and hepatitis C virus. Lancet Infect Dis 2006; 6: 8390.
  • 190
    Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 18301838.
  • 191
    Mok J, Pembrey L, Tovo PA, Newell ML. When does mother to child transmission of hepatitis C virus occur? Arch Dis Child Fetal Neonatal Ed 2005; 90: F156F160.
  • 192
    Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317: 437441.
  • 193
    Roberts SS, Miller RK, Jones JK et al. The ribavirin pregnancy registry: findings after 5 years of enrollment, 2003–2009. Birth Defects Res A Clin Mol Teratol 2010; 88: 551559.
  • 194
    Sangkomkamhang US, Lumbiganon P, Laopaiboon M. Hepatitis B vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2011; (3)CD007879.
  • 195
    Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services. 2011. 1207. Available at http://aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf (accessed April 2012).
  • 196
    American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: viral hepatitis in pregnancy. Obstet Gynecol 2007; 110: 941955.
  • 197
    Sheffield JS, Hickman A, Tang J et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011; 117: 11301135.
  • 198
    Geretti AM, Brook G, Cameron C et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795848.
  • 199
    Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283: 255260.
  • 200
    Marine-Barjoan E, Berrebi A, Giordanengo V, Favre SF et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21: 18111815.
  • 201
    European AIDS Clinical Society. European AIDS clinical society guidelines. Version 6. October 2011. Available at http://www.europeanaidsclinicalsociety.org/images/stories/%20EACS-Pdf/eacsguidelines-v6_english.pdf (accessed April 2012).
  • 202
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services 2011 [cited 2012 Jan. 14]; [1–167]. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed April 2012).
  • 203
    Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25: 967975.
  • 204
    Tural C, Fuster D, Tor J et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10: 118125.
  • 205
    Qurishi N, Kreuzberg C, Luchters G et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 17081713.
  • 206
    18+0 to 20+6 weeks fetal anomaly scan. National standards and guidance for England 2010. Available at http://fetalanomaly.screening.nhs.uk/standardsandpolicies (accessed April 2012).
  • 207
    National Institute for Health and Clinical Excellence. Antenatal care: routine care for the healthy pregnant woman. national institute of health and clinical excellence. 2008. CG62. Available at http://www.nice.org.uk/nicemedia/live/11947/40115/40115.pdf (accessed 2012).
  • 208
    Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221226.
  • 209
    Gross S, Castillo W, Crane M, Espinosa B et al. Maternal serum alpha-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus. Am J Obstet Gynecol 2003; 188: 10521056.
  • 210
    Yudin MH, Prosen TL, Landers DV. Multiple-marker screening in human immunodeficiency virus-positive pregnant women: screen positivity rates with the triple and quad screens. Am J Obstet Gynecol 2003; 189: 973976.
  • 211
    Spencer K. First and second trimester markers of fetal aneuploidy in pregnant women with HIV infection. Fetal Diagn Ther 2011; 29: 135138.
  • 212
    Einstein FH, Wright RL, Trentacoste S, Gross S, Merkatz I, Bernstein PS. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. Am J Obstet Gynecol 2004; 191: 10041008.
  • 213
    Savvidou MD, Samuel I, Syngelaki A, Poulton M, Nicolaides KH. First-trimester markers of aneuploidy in women positive for HIV. Br J Obstet Gynaecol 2011; 118: 844848.
  • 214
    Mandelbrot L, Mayaux MJ, Bongain A et al. Obstetric factors and mother to child transmission of human immunodeficiency virus type 1: the French perinatal cohort. Am J Obstet Gynecol 1996; 175: 661667.
  • 215
    Mandelbrot L, Jasseron C, Ekoukou DE et al. Amniocentesis and mother-to-child human immunodeficiency virus transmission in the Agence Nationale de Recherches sur le SIDA et les Hepatites Virales French Perinatal Cohort. Am J Obstet Gynecol 2009; 200: 160169.
  • 216
    Ekoukou D, Khuong-Josses MA, Ghibaudo N, Mechali D, Rotten D. Amniocentesis in pregnant HIV-infected patients. Absence of mother-to-child viral transmission in a series of selected patients. Eur J Obstet Gynecol Reprod Biol 2008; 140: 212217.
  • 217
    Lopez M, Coll O. Chronic viral infections and invasive procedures: risk of vertical transmission and current recommendations. Fetal Diagn Ther 2010; 28: 18.
  • 218
    Holmes WR, Hofmeyr GJ. Management of breech presentation in areas with high prevalence of HIV infection. Int J Gynaecol Obstet 2004; 87: 272276.
  • 219
    Owens M, Bhullar A, Carlan SJ, O'Brien WF, Hirano K. Effect of fundal pressure on maternal to fetal microtransfusion at the time of cesarean delivery. J Obstet Gynaecol Res 2003; 29: 152156.
  • 220
    Boer K, Nellen JF, Patel D et al. The AmRo study: pregnancy outcome in HIV-1-infected women under effective highly active antiretroviral therapy and a policy of vaginal delivery. Br J Obstet Gynaecol 2007; 114: 148155.
  • 221
    Boer K, England K, Godfried MH, Thorne C. Mode of delivery in HIV-infected pregnant women and prevention of mother-to-child transmission: changing practices in Western Europe. HIV Med 2010; 11: 368378.
  • 222
    Maiques V, Garcia-Tejedor A, Perales A, Navarro C. Intrapartum fetal invasive procedures and perinatal transmission of HIV. Eur J Obstet Gynecol Reprod Biol 1999; 87: 6367.
  • 223
    Kind C, Rudin C, Siegrist C-A et al. Prevention of vertical transmission: additive protective effect of elective caesarean section and zidovudine prophylaxis. AIDS 1998; 12: 205210.
  • 224
    National Institute of Health and Clinical Excellence. Intrapartum care: care of healthy women and their babies during childbirth. 2007. CG55. Available at http://www.nice.org.uk/guidance/CG55/NICEGuidance (accessed April 2012).
  • 225
    Tuomala RE, O'Driscoll PT, Bremer JW et al. Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral- experienced women. J Infect Dis 2003; 187: 375384.
  • 226
    Cu-Uvin S, DeLong AK, Venkatesh KK et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS 2010; 24: 24892497.
  • 227
    Neely MN, Benning L, Xu J et al. Cervical shedding of HIV-1 RNA among women with low levels of viremia while receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2007; 44: 3842.
  • 228
    National Institute of Health and Clinical Excellence. Caesarean section. 2011. CG132 Available at http://www.nice.org.uk/CG132 (accessed April 2012).
  • 229
    The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999; 340: 977987.
  • 230
    Read JS, Newell MK. Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005; (4)CD005479.
  • 231
    Townsend CL, Cortina-Borja M, Peckham CS, Tookey PA. Trends in management and outcome of pregnancies in HIV-infected women in the UK and Ireland, 1990–2006. Br J Obstet Gynaecol 2008; 115: 10781086.
  • 232
    Cavasin H, Dola T, Uribe O et al. Postoperative infectious morbidities of cesarean delivery in human immunodeficiency virus-infected women. Infect Dis Obstet Gynecol 2009; 2009: 827405.
  • 233
    Parisaei M, Anderson J, Erskine KJ, Gann S. Experience of delivering women with HIV in an inner city London hospital 1994–2004. Int J STD AIDS 2007; 18: 527530.
  • 234
    Morrison JJ, Rennie JM, Milton P. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995; 102: 101106.
  • 235
    Minkoff H, Burns DN, Landesman S et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173: 585589.
  • 236
    The International Perinatal HIV Group. Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. AIDS 2001; 15: 357368.
  • 237
    Garcia-Tejedor A, Perales A, Maiques V. Duration of ruptured membranes and extended labor are risk factors for HIV transmission. Int J Gynaecol Obstet 2003; 82: 1723.
  • 238
    Haile-Selassie H, Masters J, de Ruiter A, Tookey P. Duration of ruptured membranes and vertical transmission of HIV: data from national surveillance in the UK and Ireland. 5th Annual Conference of the Children's HIV Association. Cardiff, Wales. May 2011 [Abstract O5]. Available at http://www.chiva.org.uk/professionals/health/events/previous/conference11/oral.html (accessed April 2012).
  • 239
    Chi BH, Mudenda V, Levy J, Sinkala M, Goldenberg RL, Stringer JS. Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. Am J Obstet Gynecol 2006; 194: 174181.
  • 240
    Mofenson LM, Lambert JS, Stiehm ER et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999; 341: 385393.
  • 241
    Wabwire-Mangen F, Gray RH, Mmiro FA et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr 1999; 22: 379385.
  • 242
    National Institute of Health and Clinical Excellence. Induction of Labour. CG70. 2008. Available at http://www.nice.org.uk/CG70 (accessed April 2012).
  • 243
    Brookfield K, Dutherly L, Cotter A. Rupture of membranes greater than four hours is not a risk factor for perinatal HIV transmission in the era of combination antiretroviral therapy. Am J Obstet Gynecol 2011; 204 (Suppl 1): S42S43.
  • 244
    Royal College of Obstetricians and Gynaecologists. Antenatal corticosteroids to reduce neonatal morbidity and mortality: RCOG Greentop Guideline 7. 2010. Available at http://www.rcog.org.uk/files/rcog-corp/GTG%207.pdf (accessed April 2012).
  • 245
    Kenyon S, Boulvain M, Neilson JP. Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev 2010; (8)CD001058.
  • 246
    Frenkel LM, Cowles MK, Shapiro DE et al. Analysis of the maternal components of the AIDS clinical trial group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 971974.
  • 247
    Bhadrakom C, Simonds RJ, Mei JV et al. Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 2000; 14: 509516.
  • 248
    Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998; 12: 22812288.
  • 249
    Kully C, Yerly S, Erb P et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. Swiss Collaborative ‘HIV and Pregnancy’ Study. J Infect Dis 1999; 179: 705708.
  • 250
    Eastman PS, Shapiro DE, Coombs RW et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177: 557564.
  • 251
    Masquelier B, Chaix ML, Burgard M et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001; 27: 99104.
  • 252
    Palumbo P, Holland B, Dobbs T et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184: 11201126.
  • 253
    Welles SL, Pitt J, Colgrove RC et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the Women and Infants Transmission Study. AIDS 2000; 14: 263271.
  • 254
    Nielsen-Saines K, Watts H, Goncalces Veloso V et al. Phase III randomized trial of the safety and efficacy of three neonatal ARV regimens for prevention of intrapartum hiv-1 transmission: NICHD HPTN 040/PACTG 1043. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2011 [Abstract124LB].
  • 255
    Taha TE, Kumwenda N, Gibbons A et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission on HIV-1: NVAZ randomised clinical trial. Lancet 2003; 362: 11711177.
  • 256
    Moodley D, Moodley J, Coovadia H et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis 2003; 187: 725735.
  • 257
    Taha TE, Kumwenda NI, Hoover DR et al. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA 2004; 292: 202209.
  • 258
    Haile-Selassie H, Townsend C, Tookey P. Use of neonatal post-exposure prophylaxis for prevention of mother-to-child HIV transmission in the UK and Ireland. HIV Med 2011; 12: 422427.
  • 259
    Mandelbrot L, Landreau-Mascaro A, Rekacewicz C et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 20832093.
  • 260
    Boucher FD, Modlin JF, Weller S et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137144.
  • 261
    Mirochnick M, Nielsen-Saines K, Pilotto JH et al. Nelfinavir and lamivudine pharmacokinetics during the first two weeks of life. Pediatr Infect Dis J 2011; 30: 769772.
  • 262
    Tremoulet AH, Capparelli EV, Patel P et al. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants. Antimicrob Agents Chemother 2007; 51: 42974302.
  • 263
    Hirt D, Urien S, Rey E et al. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2009; 53: 10671073.
  • 264
    Jullien V, Urien S, Chappuy H et al. Abacavir pharmacokinetics in human immunodeficiency virus-infected children ranging in age from 1 month to 16 years: a population analysis. J Clin Pharmacol 2005; 45: 257264.
  • 265
    Benaboud S, Ekouevi DK, Urien S et al. Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2011; 55: 331337.
  • 266
    Mirochnick M, Dorenbaum A, Blanchard S et al. Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. J Acquir Immune Defic Syndr 2003; 33: 153156.
  • 267
    Mirochnick M, Nielsen-Saines K, Pilotto JH et al. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr 2008; 47: 334337.
  • 268
    Chadwick EG, Capparelli EV, Yogev R et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS 2008; 22: 249255.
  • 269
    Chadwick EG, Yogev R, Alvero CG et al. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. AIDS 2011; 25: 643649.
  • 270
    Chadwick EG, Pinto J, Yogev R et al. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy. Pediatr Infect Dis J 2009; 28: 215219.
  • 271
    Urien S, Firtion G, Anderson ST et al. Lopinavir/ritonavir population pharmacokinetics in neonates and infants. Br J Clin Pharmacol 2011; 71: 956960.
  • 272
    Simon A, Warszawski J, Kariyawasam D et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV infected mothers. JAMA 2011; 306: 7078.
  • 273
    US Food and Drug Administration. FDA Drug Safety Communication: serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. 2011. Available at http://www.fda.gov/Drugs/DrugSafety/ucm246002.htm#.Tu-NUvkx9yw.email (accessed April 2012).
  • 274
    Vankandondera J, Luchters S, Hassink E. Reducing risk of HIV-1 transmission from mother to infant through breastfeeding using antiretroviral prophylaxis in infants (SIMBA). 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris, France. July 2003 [Abstract LB07].
  • 275
    Capparelli EV, Mirochnick M, Dankner WM et al. Pharmacokinetics and tolerance of zidovudine in preterm infants. J Pediatr 2003; 142: 4752.
  • 276
    Wiznia A, Church J, Emmanuel P et al. Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients. Pediatr Infect Dis J 2007; 26: 799805.
  • 277
    Zhang X, Nieforth K, Lang JM et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 2002; 72: 1019.
  • 278
    Desfrere L, de Oliveira I, Goffinet F et al. Increased incidence of necrotizing enterocolitis in premature infants born to HIV-positive mothers. AIDS 2005; 19: 14871493.
  • 279
    Van Rompay KK, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, Pedersen NC. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995; 39: 125131.
  • 280
    Tsai CC, Emau P, Follis KE et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 42654273.
  • 281
    Bottiger D, Johansson NG, Samuelsson B et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997; 11: 157162.
  • 282
    Ferguson W, Goode M, Walsh A, Gavin P, Butler K. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. Pediatr Infect Dis J 2011; 30: 408412.
  • 283
    Lahoz R, Noguera A, Rovira N et al. Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen. Pediatr Infect Dis J 2010; 29: 376379.
  • 284
    Lallemant M, Jourdain G, Le Coeur S et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type I. N Engl J Med 2000; 343: 982991.
  • 285
    Salisbury D. Immunisation against Infectious Disease. London, Department of Health, 2006: 161184. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079917 (accessed April 2012).
  • 286
    Coutsoudis A, Dabis F, Fawzi W et al. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189: 21542166.
  • 287
    Dunn DT, Newell M-L, Ades AE, Peckham C. Estimates of the risk of HIV-1 transmission through breastfeeding. Lancet 1992; 340: 585588.
  • 288
    Nduati R, Richardson BA, John G et al. Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial. Lancet 2001; 357: 16511655.
  • 289
    Read D, The Breastfeeding and HIV International Transmission Study Group. Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. J Infect Dis 2004; 189: 21542166.
  • 290
    Nduati R, John G, Mbori-Ngacha D et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. JAMA 2000; 283: 11671174.
  • 291
    Taylor GP, Anderson J, Clayden P et al. British HIV Association and Children's HIV Association position statement on infant feeding in the UK 2011. HIV Med 2011; 12: 389393.
  • 292
    WHO, UNICEF, ANAIDS, UNFPA. HIV and Infant Feeding: A Guide for Healthcare Managers and Supervisors. Geneva, WHO, 2004. Available at http://www.who.int/maternal_child_adolescent/documents/9241591234/en/index.html (accessed April 2012).
  • 293
    Homsy J, Moore D, Barasa A et al. Breastfeeding, mother-to-child HIV transmission, and mortality among infants born to HIV-infected women on highly active antiretroviral therapy in rural Uganda. J Acquir Immune Defic Syndr 2009; 53: 2835.
  • 294
    Kilewo C, Karlsson K, Ngarina M et al. Prevention of mother-to-child transmission of HIV-1 through breastfeeding by treating mothers with triple antiretroviral therapy in Dar es Salaam, Tanzania: the Mitra Plus Study. J Acquir Immune Defic Syndr 2009; 52: 406416.
  • 295
    Marazzi MC, Nielsen-Saines K, Buonomo E et al. Increased infant human immunodeficiency virus-type one free survival at one year of age in sub-Saharan Africa with maternal use of highly active antiretroviral therapy during breast-feeding. Pediatr Infect Dis J 2009; 28: 483487.
  • 296
    Peltier CA, Ndayisaba GF, Lepage P et al. Breastfeeding with maternal antiretroviral therapy or formula feeding to prevent HIV postnatal mother-to-child transmission in Rwanda. AIDS 2009; 23: 24152423.
  • 297
    Chasela CS, Hudgens MG, Jamieson DJ et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med 2010; 362: 22712281.
  • 298
    Fawzy A, Arpadi S, Kankasa C et al. Early Weaning increases diarrhea morbidity and mortality among uninfected children born to HIV-infected mothers in Zambia. J Infect Dis 2011; 203: 12221230.
  • 299
    Kafulafala G, Hoover DR, Taha TE et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53: 613.
  • 300
    World Health Organization. Guidelines on HIV and infant feeding 2010: principles and recommendations for infant feeding in the context of HIV and a summary of evidence. 2010. Available at http://www.who.int/maternal_child_adolescent/documents/9789241599535/en/ (accessed April 2012).
  • 301
    Kilewo C, Karlsson K, Massawe A et al. Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study. J Acquir Immune Defic Syndr 2008; 48: 315323.
  • 302
    Shapiro RL, Ndung'u T, Lockman S et al. Highly active antiretroviral therapy started during pregnancy or postpartum suppresses HIV-1 RNA, but not DNA, in breast milk. J Infect Dis 2005; 192: 713719.
  • 303
    Valea D, Tuaillon E, Al TY et al. CD4+ T cells spontaneously producing human immunodeficiency virus type I in breast milk from women with or without antiretroviral drugs. Retrovirology 2011; 8: 34.
  • 304
    House of Lords Select Committee on HIV and AIDS in the United Kingdom. No Vaccine, No Cure: HIV and AIDS in the United Kingdom. London, The Stationery Office Limited, 2011: Available at http://www.publications.parliament.uk/pa/ld201012/ldselect/ldaids/188/188.pdf (accessed April 2012).
  • 305
    Coutsoudis A, Pillay K, Kuhn L, Spooner E, Tsai WY, Coovadia HM. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS 2001; 15: 379387.
  • 306
    Centers of Disease Control and Prevention (CDC). Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures – worldwide, 1997–2000. MMWR Morb Mortal Wkly Rep 2001; 49: 11531156.
  • 307
    Lambert JS, Harris DR, Stiehm ER et al. Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection. J Acquir Immune Defic Syndr 2003; 34: 512519.
  • 308
    Burgard M, Blanche S, Jasseron C et al. Performance of HIV-1 DNA or HIV-1 RNA tests for early diagnosis of perinatal HIV-1 infection during anti-retroviral prophylaxis. J Pediatr 2012; 160: 6066.
  • 309
    Burgard M, Blanche S, Mayaux M et al. Impact of neonatal prophylaxis on early diagnosis in newborns. 10th Conference on Retroviruses and Opportunistic Infections. Boston, MA. February 2003 [Abstract 868].
  • 310
    Nastouli E, Atkins M, Seery P, Hamadache D, Lyall H. False-positive HIV antibody results with ultrasensitive serological assays in uninfected infants born to mothers with HIV. AIDS 2007; 21: 12221223.
  • 311
    Frange P, Burgard M, Lachassinne E et al. Late postnatal HIV infection in children born to HIV-1-infected mothers in a high-income country. AIDS 2010; 24: 17711776.
  • 312
    Department of Health. Children's HIV National Network (CHINN) Review 2005. 2006. Available at http://www.dh.%20gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/%20documents/digitalasset/dh_4139815.pdf (accessed April 2012).
  • 313
    Wood C, Kumalo P, Ainsworth J, Govind A, Meates M. Disclosure, discordance and decisions: the psychosocial impact of antenatal HIV testing. 2002. 6th International Congress On Drug Therapy in HIV Infection. Glasgow, UK. November [Abstract P319].
  • 314
    Wood C, Ellison G. What have clinicians learnt from working with HIV/AIDS? A medical perspective from London. In: Ellison G , Parker M , Campbell C , eds. Learning from HIV/AIDS. Cambridge, Cambridge University Press, 2003: 105137.
  • 315
    Siriwasin W, Shaffer N, Roongpisuthipong A et al. HIV prevalence, risk, and partner serodiscordance among pregnant women in Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. JAMA 1998; 280: 4954.
  • 316
    Guilen AC, Fogarty L, O'Campo P, Anderson J, Keller J, Faden R. Women living with HIV: disclosure, violence, and social support. J Urban Health 2000; 77: 480491.
  • 317
    Stein MD, Freedberg KA, Sullivan LM et al. Sexual ethics. Disclosure of HIV positive status to partners. Arch Int Med 1998; 158: 253257.
  • 318
    WHO Department of Gender, Women and Health; WHO Cluster of Family and Community Health. Gender dimensions of HIV status disclosure to sexual partners: rates, barriers and outcomes for women. World Health Organization. 2003. Available at http://www.who.int/gender/documents/women_and_girls/9241590734/en/ (accessed April 2012).
  • 319
    General Medical Council. Confidentiality: disclosing information about serious communicable diseases. General Medical Council. 2009; Available at http://www.gmc-%20uk.org/Confidentiality_disclosing_info_serious_commun_%20diseases_2009.pdf_27493404.pdf (accessed April 2012).
  • 320
    Serovich JM. Helping HIV-positive persons to negotiate the disclosure process to partners, family members, and friends. J Marital Fam Ther 2000; 26: 365372.
  • 321
    Freeman E, Glynn J, for the Study Group on Heterogeneity of HIV epidemics in African Cities. Factors affecting HIV concordancy in married couples in four African cities. AIDS 2004; 18: 17151720.
  • 322
    Benn P, Fisher M, Kulasegaram R. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS 2011; 22: 695708.
  • 323
    UK Chief Medical Officers' Expert Advisory Group on AIDS. HIV and Infant Feeding: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS. Department of Health. 2004. Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAnd%20Guidance/DH_4089892 (accessed April 2012).
  • 324
    Creighton S, Sethi G, Edwards SG, Miller R. Dispersal of HIV positive asylum seekers: national survey of UK healthcare providers. BMJ 2004; 329: 322323.
  • 325
    National AIDS Trust and British HIV Association. The dispersal process for asylum seekers living with HIV: advice for health care and voluntary sector professionals. National AIDS Trust. 2006. Available at http://www.nat.org.uk/%20Media%20Library/Files/PDF%20documents/NAT-Dispersal-%20Process-For-Asylum-Seekers.pdf (accessed April 2012).
  • 326
    National AIDS Trust and British HIV Association. Detention, removal and people living with HIV: advice for health care and voluntary sector professionals. National AIDS Trust. 2009. Available at http://www.nat.org.uk/%20Media%20library/Files/Policy/Poverty%20and%20Social%20%20Disadvantage/NAT%20and%20BHIVA%20Booklet%20on%20%20HIV%20and%20Removal%20Centres%20(June%202009)%20%20EMAIL-1.pdf (accessed April 2012).
  • 327
    British HIV Association, Children's HIV Association, British Association for Sexual Health and HIV. ‘Don't forget the children’. Guidance for the HIV testing of children with HIV-positive parents. Children's HIV Association. 2009. Available at http://www.chiva.org.uk/files/guidelines/dont-forget.pdf (accessed April 2012).
  • 328
    British Psychological Society, British HIV Association, Medical Foundation for AIDS and Sexual Health. Standards for psychological support of adults living with HIV. MedFASH. 2011. Available at http://www.bhiva.org/StandardsForPsychologicalSupport.aspx (accessed April 2012).
  • 329
    National Institute of Health and Clinical Excellence. Antenatal and Postnatal Mental Health: clinical Management and Service Guidance. CG45. 2007. Available at http://guidance.nice.org.uk/CG45/NICEGuidance/pdf/English (accessed April 2012).
  • 330
    Moodley D, Pillay K, Naidoo K et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clin Pharmacol 2001; 41: 732741.
  • 331
    Frasca K, Fisher RG, McGuire E. Alternative dosage of zidovudine in infants exposed to maternal human immunodeficiency virus infection. Pediatr Infect Dis J 2009; 28: 11311132.
  • 332
    Alimenti A, Burdge DR, Ogilvie GS, Money DM, Forbes JC. Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy. Pediatr Infect Dis J 2003; 22: 782789.
  • 333
    Durand-Gasselin L, Pruvost A, Dehee A et al. High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents Chemother 2008; 52: 25552563.
  • 334
    Hirt D, Pruvost A, Ekouevi DK et al. Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob Agents Chemother 2011; 55: 29532960.
  • 335
    Shetty AK, Coovadia HM, Mirochnick M et al. Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months. J Acquir Immune Defic Syndr 2004; 34: 482490.
  • 336
    Jullien V, Urien S, Hirt D et al. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob Agents Chemother 2006; 50: 35483555.
  • 337
    Verweel G, Burger DM, Sheehan NL et al. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther 2007; 12: 453458.
  • 338
    Simonds RJ, Lindegren ML, Thomas P et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group. N Engl J Med 1995; 332: 786790.